ES555199A0 - Procedimiento para preparar analogos imidazolicos de mevalonolactona y derivados de los mismos - Google Patents

Procedimiento para preparar analogos imidazolicos de mevalonolactona y derivados de los mismos

Info

Publication number
ES555199A0
ES555199A0 ES555199A ES555199A ES555199A0 ES 555199 A0 ES555199 A0 ES 555199A0 ES 555199 A ES555199 A ES 555199A ES 555199 A ES555199 A ES 555199A ES 555199 A0 ES555199 A0 ES 555199A0
Authority
ES
Spain
Prior art keywords
imidazolic
mevalonolactone
analogs
derivatives
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES555199A
Other languages
English (en)
Other versions
ES8707191A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of ES555199A0 publication Critical patent/ES555199A0/es
Publication of ES8707191A1 publication Critical patent/ES8707191A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/02—Optical fibres with cladding with or without a coating
    • G02B6/02033—Core or cladding made from organic material, e.g. polymeric material
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/44—Mechanical structures for providing tensile strength and external protection for fibres, e.g. optical transmission cables
    • G02B6/4401—Optical cables
    • G02B6/4429—Means specially adapted for strengthening or protecting the cables
    • G02B6/443—Protective covering
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/44—Mechanical structures for providing tensile strength and external protection for fibres, e.g. optical transmission cables
    • G02B6/4401—Optical cables
    • G02B6/4429—Means specially adapted for strengthening or protecting the cables
    • G02B6/4436—Heat resistant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/05—Filamentary, e.g. strands
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber
    • Y10T428/2933—Coated or with bond, impregnation or core
    • Y10T428/2938—Coating on discrete and individual rods, strands or filaments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber
    • Y10T428/2933—Coated or with bond, impregnation or core
    • Y10T428/2962—Silane, silicone or siloxane in coating
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber
    • Y10T428/2933—Coated or with bond, impregnation or core
    • Y10T428/2964—Artificial fiber or filament
    • Y10T428/2967—Synthetic resin or polymer
ES555199A 1985-05-22 1986-05-21 Procedimiento para preparar analogos imidazolicos de mevalonolactona y derivados de los mismos Expired ES8707191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/736,679 US4668794A (en) 1985-05-22 1985-05-22 Intermediate imidazole acrolein analogs

Publications (2)

Publication Number Publication Date
ES555199A0 true ES555199A0 (es) 1987-07-16
ES8707191A1 ES8707191A1 (es) 1987-07-16

Family

ID=24960855

Family Applications (1)

Application Number Title Priority Date Filing Date
ES555199A Expired ES8707191A1 (es) 1985-05-22 1986-05-21 Procedimiento para preparar analogos imidazolicos de mevalonolactona y derivados de los mismos

Country Status (18)

Country Link
US (1) US4668794A (es)
EP (1) EP0235164B1 (es)
JP (1) JPS62502894A (es)
KR (1) KR910003428B1 (es)
AU (1) AU594064B2 (es)
DE (1) DE3673003D1 (es)
DK (1) DK33287A (es)
ES (1) ES8707191A1 (es)
FI (1) FI865162A0 (es)
GR (1) GR861319B (es)
HU (1) HUT41743A (es)
IL (1) IL78858A (es)
NZ (1) NZ216234A (es)
PH (1) PH25768A (es)
PL (1) PL149929B1 (es)
PT (1) PT82623B (es)
WO (1) WO1986007054A1 (es)
ZA (1) ZA863840B (es)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6322056A (ja) * 1986-04-30 1988-01-29 サンド・アクチエンゲゼルシヤフト オレフイン性化合物の製造法
IL83821A0 (en) * 1986-09-10 1988-02-29 Sandoz Ag Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
US4898949A (en) * 1987-02-25 1990-02-06 Bristol-Myers Company Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US5300252A (en) * 1987-03-13 1994-04-05 Fmc Corporation Ether free organometallic amide compositions
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US4761419A (en) * 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) * 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
US5010205A (en) * 1988-08-23 1991-04-23 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl intermediates
US4870187A (en) * 1988-08-23 1989-09-26 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl compounds
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
IT1237470B (it) * 1988-10-03 1993-06-07 Glaxo Group Ltd Derivati di imidazolo, procedimenti per produrli e composizioni farmaceutiche che li contengono
NZ230973A (en) * 1988-10-13 1993-03-26 Sandoz Ltd Process for the preparation of 7-substituted, hept-6-enoic and heptanoic acids and selected derivatives and optical isomers
ATE190051T1 (de) * 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
US5418250A (en) * 1989-06-14 1995-05-23 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5106992A (en) * 1989-07-28 1992-04-21 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
JPH03184961A (ja) * 1989-10-10 1991-08-12 Glaxo Group Ltd 化合物
US5177096A (en) * 1989-10-25 1993-01-05 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US5011851A (en) * 1990-02-13 1991-04-30 Bristol-Myers Squibb Co. Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US5049578A (en) * 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
GB9213934D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
US5728842A (en) * 1992-06-30 1998-03-17 Smithkline Beecham Corporation Substituted imidazolyl-alkylthio-alkanoic acids
FR2696746B1 (fr) * 1992-10-12 1994-11-18 Synthelabo Dérivés de l'acide benzèneborinique, leur préparation et leur utilisation comme intermédiaires de synthèse.
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
CA2444481A1 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US6747048B2 (en) 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AU2003241477A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
JP3788479B2 (ja) 2003-05-21 2006-06-21 株式会社ジェイ・エム・エス 血清調製用容器及びそれを用いた血清調製方法
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1725234B2 (en) 2004-03-05 2016-02-24 The Trustees of The University of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006087630A2 (en) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
EP1943215A2 (en) 2005-10-31 2008-07-16 Brystol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
AU2008287542C1 (en) 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP2010534722A (ja) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
EP2197873B1 (en) 2007-09-20 2014-07-16 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009073564A1 (en) * 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US8575168B2 (en) 2009-10-09 2013-11-05 Irm Llc Compounds and compositions as modulators of GPR119 activity
MX2012005365A (es) 2009-11-13 2012-05-29 Bristol Myers Squibb Co Formulaciones de tableta de liberacion inmediata.
CA2780938A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
PL2498758T3 (pl) 2009-11-13 2019-02-28 Astrazeneca Ab Formulacje tabletek dwuwarstwowych
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
ES2575860T3 (es) 2010-07-09 2016-07-01 Bhv Pharma, Inc. Sistema de administración de liberación inmediata/retardada de combinación para productos farmacéuticos de semivida corta que incluyen remogliflozina
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
DK2925735T3 (da) 2012-11-20 2019-06-17 Lexicon Pharmaceuticals Inc Inhibitorer for natriumglucose-cotransporter 1
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
CA3113037A1 (en) 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (es) * 1974-06-07 1981-03-18
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
JPS5559140A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 3,5-dihydroxypentanoic alkyl ester derivative, its preparation and remedy for hyperlipemia containing the same as the effective component
JPS5559180A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent
JPS567775A (en) * 1979-06-29 1981-01-27 Sankyo Co Ltd 4-alkoxy-2-pyrrone derivative
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4351844A (en) * 1980-02-04 1982-09-28 Merck & Co., Inc. Hypocholesterolemic hydrogenation products and process of preparation
PT72801B (en) * 1980-04-14 1983-01-10 Merck & Co Inc Process for synthesis of substituted biphenyl-2-carboxaldehydes
JPS56150037A (en) * 1980-04-22 1981-11-20 Sankyo Co Ltd Hydronaphthalene compound
US4308378A (en) * 1980-09-02 1981-12-29 Merck & Co., Inc. Cis/trans isomerization of 6-(substituted-aryl-ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-ones
US4440927A (en) * 1981-06-19 1984-04-03 Merck & Co., Inc. Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase via a chiral synthon
EP0068038B1 (en) * 1981-06-29 1985-09-25 Merck & Co. Inc. (+)-(4r,6s)-(e)-6-(2-(4'-fluoro-3,3',5-trimethyl-(1,1'-biphenyl)-2-yl)ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2h-pyran-2-one, a process for preparing and a pharmaceutical composition containing the same
US4376863A (en) * 1981-08-21 1983-03-15 Merck & Co., Inc. Hypocholesterolemic fermentation products
US4387242A (en) * 1981-08-21 1983-06-07 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
AU9133682A (en) * 1981-12-23 1983-06-30 Akira Endo Dihydro- and tetrahydromonacolin l- and their salts and esters
US4474971A (en) * 1982-09-29 1984-10-02 Sandoz, Inc. (Tetrahydropyran-2-yl)-aldehydes
WO1984002131A1 (en) * 1982-11-22 1984-06-07 Sandoz Ag Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4503072A (en) * 1982-12-22 1985-03-05 Merck & Co., Inc. Antihypercholesterolemic compounds
EP0117228B1 (en) * 1983-01-24 1986-11-05 Sandoz Ag Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4530922A (en) * 1984-01-03 1985-07-23 E. I. Du Pont De Nemours And Company Fungicidal imidazoles and triazoles containing silicon
KR890001651B1 (ko) * 1984-06-22 1989-05-12 산도즈 파마슈티칼스 코포레이션 메발로노락톤의 피라졸 동족체 및 이의 유도체의 제조방법

Also Published As

Publication number Publication date
HUT41743A (en) 1987-05-28
NZ216234A (en) 1990-01-29
IL78858A0 (en) 1986-09-30
EP0235164A1 (en) 1987-09-09
KR910003428B1 (ko) 1991-05-31
PH25768A (en) 1991-10-18
AU5960686A (en) 1986-12-24
DE3673003D1 (de) 1990-08-30
FI865162A (fi) 1986-12-17
US4668794A (en) 1987-05-26
FI865162A0 (fi) 1986-12-17
PL149929B1 (en) 1990-04-30
EP0235164B1 (en) 1990-07-25
ZA863840B (en) 1987-12-30
KR870700607A (ko) 1987-12-30
AU594064B2 (en) 1990-03-01
WO1986007054A1 (en) 1986-12-04
PT82623A (en) 1986-06-01
ES8707191A1 (es) 1987-07-16
DK33287D0 (da) 1987-01-21
IL78858A (en) 1991-03-10
GR861319B (en) 1986-09-19
JPS62502894A (ja) 1987-11-19
DK33287A (da) 1987-01-21
PT82623B (pt) 1988-08-17

Similar Documents

Publication Publication Date Title
ES555199A0 (es) Procedimiento para preparar analogos imidazolicos de mevalonolactona y derivados de los mismos
ES556320A0 (es) Procedimiento para la obtencion de derivados del 3-fenil-4-cianopirrol
ES552432A0 (es) Procedimiento para preparar derivados de urea
NO169014C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive distamycinderivater
NO167026C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
ES556026A0 (es) Un procedimiento para preparar derivados de tienopiridona
NO168826C (no) Analogifremgangsmaate for fremstilling av poly-4-aminopyrrol-2-karboksamidoderivater
ES551069A0 (es) Procedimiento para la preparacion de derivados de 13beta-alquil-milbenicina
ES543686A0 (es) Procedimiento para preparar derivados de acidos quinolincar-boxilicos
NO171592C (no) Fremgangsmaate for fremstilling av aktive cinnolin-derivater
ES557395A0 (es) Un procedimiento para preparar derivados arilicos de dienamidas
ES527428A0 (es) Procedimiento para preparar analogos de mevalono-lactona y derivados de los mismos
AR240815A1 (es) Procedimiento para preparar derivados de los acidos benzofuran-5-il y benzotiofen-5-il acetico y propionico
ES545454A0 (es) Procedimiento para la preparacion de compuestos naftil-ana- logos de mevalonolactona y sus derivados
ES557389A0 (es) Procedimiento para preparar 1,2-dihidronaftalenos y derivados 1-oxa, 1-tia 1-sulfinilo y 1-sulfonilo de los mismos
ES549116A0 (es) Procedimiento para obtencion de derivados de flavolignano
ES554371A0 (es) Procedimiento para preparar derivados de benzisoselenazolilo
ES555709A0 (es) Procedimiento para preparar nuevos derivados del fenantreno
ES553467A0 (es) Un procedimiento para preparar derivados de dihidropiridazina
ES551957A0 (es) Procedimiento para la preparacion de derivados de alcano aromaticos
ES555278A0 (es) Procedimiento para la obtencion de derivados de diclorociclopropilalquilhidroxialquil-azol
ES557468A0 (es) Procedimiento para preparar derivados de pirazol y bencimidazol
ES543324A0 (es) Procedimiento de obtencion de nuevos derivados imidazolicos de los acidos indanocarboxilicos
ES541876A0 (es) Procedimiento para preparar derivados de 14-hidroxiimino- eburnano racemicos y opticamente activos
ES544130A0 (es) Procedimiento para la obtencion de derivados de pirrolpro- pionitrilo

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960506